Faculty Affiliations

G Thomas Budd, MD Professor of Medicine, Cleveland Clinic Lerner College of Medicine Cleveland Clinic Foundation Cleveland, Ohio Rowan T Chlebowski, MD, PhD Professor of Medicine, David Geffen School of Medicine at UCLA; Chief Division of Medical Oncology and Hematology, Harbor-UCLA Medical Center Torrance, California John F Forbes, MD Professor, University of Newcastle Director, Department of Surgical Oncology, Calvary Mater Newcastle Hospital Newcastle, New South Wales, Australia Clifford Hudis, MD Chief, Breast Cancer Medicine Service Solid Tumor Division, Department of Medicine Memorial Sloan-Kettering Cancer Center New York, New York

Joyce O’Shaughnessy, MD Co-Director, Breast Cancer Research Program Baylor-Charles A Sammons Cancer Center Texas Oncology, PA, US Oncology Dallas, Texas George W Sledge Jr, MD Ballve-Lantero Professor of Oncology Professor of Medicine and Pathology Melvin and Bren Simon Indiana University Cancer Center Indianapolis, Indiana Joseph A Sparano, MD Professor of Medicine and Women’s Health, Albert Einstein College of Medicine; Associate Chairman, Department of Oncology Montefiore Medical Center Director, Breast Evaluation Center Montefiore-Einstein Cancer Center Bronx, New York

CONTENT VALIDATION AND DISCLOSURES

Research To Practice is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the Research To Practice scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The following scientific staff and reviewers for Research To Practice reported real or apparent conflicts of interest for themselves (or their spouses/ partners), which have been resolved through a conflict of interest resolution process:

Aviva Asnis-Alibozek, PA-C, MPAS
Salary: AstraZeneca Pharmaceuticals LP. Shareholder of: AstraZeneca Pharmaceuticals LP.

Sally Bogert, RNC, WHCNP
Shareholder of: Amgen Inc and Genentech BioOncology.

All other Research To Practice staff and external reviewers:
No real or apparent conflicts of interest to report.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

Dr Budd
Consulting Fees: AstraZeneca Pharmaceuticals LP, Pfizer Inc.

Dr Chlebowski
Consulting Fees: AstraZeneca Pharmaceuticals LP, Novartis Pharmaceuticals Corporation, Pfizer Inc. Fees for Non-CME Services Received Directly from Commercial Interest or Their Agents: AstraZeneca Pharmaceuticals LP, Novartis Pharmaceuticals Corporation.

Prof Forbes
Consulting Fees: Novartis Pharmaceuticals Corporation. Fees for Non-CME Services Received Directly from Commercial Interest or Their Agents: AstraZeneca Pharmaceuticals LP, Novartis Pharmaceuticals Corporation.

Dr Hudis
Consulting Fees: Abraxis BioScience, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech BioOncology, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc, Sanofi-Aventis. Contracted Research: Kosan Biosciences. Fees for Non-CME Services Received Directly from Commercial Interest or Their Agents: AstraZeneca Pharmaceuticals LP. Ownership Interest: Genomic Health Inc.

Dr O’Shaughnessy
Consulting Fees: Biogen Idec, Bristol- Myers Squibb Company, Eisai Inc, Eli Lilly and Company, Genentech BioOncology, Genzyme Corporation, Novartis Pharmaceuticals Corporation, Ortho Biotech Products LP, Pfizer Inc. Fees for Non-CME Services Received Directly from Commercial Interest or Their Agents: Abraxis BioScience, Eli Lilly and Company, Sanofi-Aventis.

Dr Sledge
Consulting Fees: Genentech BioOncology. Contracted Research: Sanofi-Aventis.

Dr Sparano
Consulting Fees: Bristol-Myers Squibb Company, Eisai Inc, Genentech BioOncology, GlaxoSmithKline, Johnson & Johnson Pharmaceuticals, Merck and Company Inc, Sanofi-Aventis.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.